PuSH - Publication Server of Helmholtz Zentrum München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Finan, B. ; Ma, T.* ; Ottaway, N.* ; Müller, T.D. ; Habegger, K.M.* ; Heppner, K.M.* ; Kirchner, H.* ; Holland, J.* ; Hembree, J.* ; Raver, C.* ; Lockie, S.H.* ; Smiley, D.L.* ; Gelfanov, V.* ; Yang, B.* ; Hofmann, S. ; Bruemmer, D.* ; Drucker, D.J.* ; Pfluger, P.T. ; Perez-Tilve, D.* ; Gidda, J.* ; Vignati, L.* ; Zhang, L.* ; Hauptman, J.B.* ; Lau, M.* ; Brecheisen, M.* ; Uhles, S.* ; Riboulet, W.* ; Hainaut, E.* ; Sebokova, E.* ; Conde-Knape, K.* ; Konkar, A.* ; DiMarchi, R.D.* ; Tschöp, M.H.

Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans.

Sci. Transl. Med. 5:209ra151 (2013)
Publ. Version/Full Text Volltext DOI PMC
Closed
Open Access Green as soon as Postprint is submitted to ZB.
We report the discovery and translational therapeutic efficacy of a peptide with potent, balanced co-agonism at both of the receptors for the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). This unimolecular dual incretin is derived from an intermixed sequence of GLP-1 and GIP, and demonstrated enhanced antihyperglycemic and insulinotropic efficacy relative to selective GLP-1 agonists. Notably, this superior efficacy translated across rodent models of obesity and diabetes, including db/db mice and ZDF rats, to primates (cynomolgus monkeys and humans). Furthermore, this co-agonist exhibited synergism in reducing fat mass in obese rodents, whereas a selective GIP agonist demonstrated negligible weight-lowering efficacy. The unimolecular dual incretins corrected two causal mechanisms of diabesity, adiposity-induced insulin resistance and pancreatic insulin deficiency, more effectively than did selective mono-agonists. The duration of action of the unimolecular dual incretins was refined through site-specific lipidation or PEGylation to support less frequent administration. These peptides provide comparable pharmacology to the native peptides and enhanced efficacy relative to similarly modified selective GLP-1 agonists. The pharmacokinetic enhancement lessened peak drug exposure and, in combination with less dependence on GLP-1-mediated pharmacology, avoided the adverse gastrointestinal effects that typify selective GLP-1-based agonists. This discovery and validation of a balanced and high-potency dual incretin agonist enables a more physiological approach to management of diseases associated with impaired glucose tolerance.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
10.757
3.006
294
333
Tags
Annotations
Special Publikation
Hide on homepage

Edit extra information
Edit own tags
Private
Edit own annotation
Private
Hide on publication lists
on hompage
Mark as special
publikation
Publication type Article: Journal article
Document type Scientific Article
Keywords Dependent Insulinotropic Polypeptide ; Gastric-inhibitory Polypeptide ; High-fat Diet ; Pancreatic Beta-cells ; Glucose-intolerance ; Enteroinsular Axis ; Lipoprotein-lipase ; Glycemic Control ; Peptide Yy3-36 ; Body-weight
Language english
Publication Year 2013
HGF-reported in Year 2013
ISSN (print) / ISBN 1946-6234
e-ISSN 1946-6242
Journal Science Translational Medicine
Quellenangaben Volume: 5, Issue: 209, Pages: , Article Number: 209ra151 Supplement: ,
Publisher American Association for the Advancement of Science (AAAS)
Reviewing status Peer reviewed
Institute(s) Institute of Diabetes and Obesity (IDO)
Institute of Diabetes and Regeneration Research (IDR)
POF-Topic(s) 30201 - Metabolic Health
90000 - German Center for Diabetes Research
Research field(s) Helmholtz Diabetes Center
PSP Element(s) G-502200-001
G-501900-221
G-502390-001
PubMed ID 24174327
DOI 10.1126/scitranslmed.3007218
WOS ID WOS:000326501700004
Scopus ID 84890043525
Erfassungsdatum 2013-12-19
[➜Report correction]